AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24521887
Drug: LACJ (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACJ (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + jinghuaweikang gelatin pearls 240 mg, twice daily for 10 days, then jinghuaweikang gelatin pearls 240 mg, twice daily for 14 days)
Trial: 24521887
Drug: LACB (lansoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LACB (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg, twice daily for 10 days)
Trial: 21248360
Drug: Intra‐esophageal infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐esophageal infusion of 5‐mL acidic solution (0.1 N HCl)
Trial: 16984212
Drug: Traxoprodil 100mg
RxNorm normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil 100mg oral dose
Trial: 16984212
Drug: Traxoprodil 50mg
RxNorm normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil 50mg oral dose
Trial: 16984212
Drug: Traxoprodil 300mg
RxNorm normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil 300mg oral dose
Trial: 16984212
Drug: Traxoprodil 50mg
RxNorm normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil 50mg intravenous infusion
Trial: 16984212
Drug: Traxoprodil 100mg
RxNorm normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil 100mg intravenous infusion
Trial: 16984212
Drug: Traxoprodil oral
RxNorm normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil oral administration in poor metabolisers
Trial: 16984212
Drug: Traxoprodil oral
RxNorm normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traxoprodil oral administration in extensive metabolisers
Trial: 8956766
Drug: Control enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control enteral formula (1 L/d for 7 days before surgery)
Trial: 8956766
Drug: Enriched enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched enteral formula (1 L/d for 7 days before surgery, enriched with arginine, RNA, and omega-3 fatty acids)
Trial: 8005921
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Guargum (10 grams) and Acarbose (50 grams)
Trial: 8005921
Drug: Control (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (without trial drugs)
Trial: 27717336
Drug: Early enteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early enteral feeding (first feeding bolus with a polymeric diet (1 kcal/ml) via a feeding tube 3 hours after PEG placement)
Trial: 16536766
Drug: Naftopidil 50
RxNorm normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Naftopidil 50 mg for 4 weeks
Trial: 16536766
Drug: Tamsulosin 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.2 mg for 4 weeks
Trial: 14642684
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg/day for 8 weeks followed by 8 mg/day for 4 weeks)
Trial: 9436940
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN) combined with chemotherapy
Trial: 9436940
Drug: IFN maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN maintenance therapy
Trial: 3676158
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Fe
Trial: 30033619
Drug: FAB 10
RxNorm normalized name: digoxin immune FAB 10 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAB 10 (esomeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Trial: 30033619
Drug: FA 10
RxNorm normalized name: IDHIFA 100mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA 10 (esomeprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days, without bismuth)
Trial: 22490404
Drug: Standard antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antithrombotic therapy for two weeks
Trial: 20602497
Drug: Postoperative magnesium
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative magnesium hydroxide as a laxative
Trial: 20602497
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of laxative and ONS
Trial: 8978112
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment preferences
Trial: 4017670
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml of 100-proof vodka per kg of body weight in orange juice
Trial: 29804794
Drug: Oral immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral immunotherapy (OIT) with pasteurized raw egg white
Trial: 29804794
Drug: IgE specific
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgE specific of ovomucoid titer <2.045kU/l
Trial: 24863631
Drug: 10-20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-20 ml/kg FFP (FFP group, n=50)
Trial: 24863631
Drug: 10-20 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-20 ml/kg 4% succinylated gelatin (Gelofusine, GEL group, n=50)
Trial: 22207015
Drug: Guideline for
RxNorm normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline for initiation and maintenance of insulin infusions for hyperglycemia
Trial: 15948160
Drug: RT after
RxNorm normalized name: Lotion, Multi Ingredient Topical application Lotion [COPPERTONE SPORT AFTER SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT after the third chemotherapy cycle
Trial: 15948160
Drug: RT after
RxNorm normalized name: Lotion, Multi Ingredient Topical application Lotion [COPPERTONE SPORT AFTER SUN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT after the sixth chemotherapy cycle
Trial: 15948160
Drug: 1-3 chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-3 chemotherapy cycles
Trial: 8955656
Drug: Dexrazoxane (10:1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexrazoxane (10:1 dose ratio with epirubicin)
Trial: 6662683
Drug: azlocillin-gentamicin (AZ-G)
RxNorm normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: azlocillin-gentamicin (AZ-G)
Trial: 6662683
Drug: ampicillin-gentamicin (AM-G)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ampicillin-gentamicin (AM-G)
Trial: 26888417
Drug: Spirulina supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina supplementation (3 g/day)
Trial: 17509103
Drug: Lubiprostone 24
RxNorm normalized name: LUBIPROSTONE 24MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubiprostone 24 mcg/day
Trial: 17509103
Drug: Lubiprostone 48
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone 48 mcg/day
Trial: 17509103
Drug: Lubiprostone 72
RxNorm normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubiprostone 72 mcg/day
Trial: 16307962
Drug: Drospirenone 3
RxNorm normalized name: drospirenone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone 3 mg and ethinyl estradiol (EE) 20 mcg
Trial: 9701720
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 times daily for 6 days)
Trial: 2539180
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir 5 mg kg‐1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6‐hourly for 6 months
Trial: 2539180
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir and oral acyclovir
Trial: 773085
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B lozenges
Trial: 28120017
Drug: Distal sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distal sciatic nerve block (DSB) out-of-plane with 30 ml of Mepivacaine 1%
Trial: 28120017
Drug: Proximal sciatic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proximal sciatic nerve block (DSB) in-plane with 30 ml of Mepivacaine 1%
Trial: 11414530
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol via Jet nebulizer
Trial: 11414530
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol via MDI-spacer
Trial: 2443539
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg prednisone per day for 2 days before challenge
Trial: 29696921
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with fluoxetine
Trial: 29696921
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture combined with fluoxetine
Trial: 27706466
Drug: Conservative oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative oxygen therapy (maintaining Pao2 between 70 and 100 mm Hg or Spo2 between 94% and 98%)
Trial: 27706466
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (allowing Pao2 values up to 150 mm Hg or Spo2 between 97% and 100%)
Trial: 1538721
Drug: Continuous medical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous medical therapy (lifestyle modifications and up to four medications)
Trial: 1538721
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for symptoms only
Trial: 1538721
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (Nissen fundoplication)
Trial: 24419307
Drug: EVP-6124 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 0.3 mg (n=8)
Trial: 24419307
Drug: EVP-6124 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 1.0 mg (n=9)
Trial: 24419307
Drug: EVP-6124 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVP-6124 (0.3 mg and 1.0 mg)
Trial: 12405434
Drug: Early interventional
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early interventional therapy
Trial: 10091789
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2) followed by IL-2 (18 x 10(6) IU/m2) on Days 3-6 and Days 17-21 (Arm 1)
Trial: 10091789
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and IL-2 with subcutaneous IFN (9 x 10(6) U, 3 times a week during IL-2 administration) (Arm 2)
Trial: 8573537
Drug: Weekly dose-intensive
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly dose-intensive chemotherapy
Trial: 8573537
Drug: 3-weekly conventional
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-weekly conventional chemotherapy
Trial: 465271
Drug: Droperidol 2.5
RxNorm normalized name: droperidol 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 2.5 mg with Diazepam 5 mg
Trial: 465271
Drug: Larger doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger doses of droperidol with diazepam
Trial: 465271
Drug: Larger doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger doses of diazepam with droperidol
Trial: 21266516
Drug: Irinotecan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 50 mg/m2 on days 1, 8, and 15 combined with carboplatin AUC 5 mg x min/ml
Trial: 21266516
Drug: Etoposide 140
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 140 mg/m2 on days 1-3 combined with carboplatin AUC 5 mg x min/ml
Trial: 15500532
Drug: Acupressure at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure at Sanyinjiao point (self-treatment follow-up)
Trial: 9630110
Drug: Ibutilide low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide low dose (0.005 mg/kg + 0.001 mg/kg)
Trial: 9630110
Drug: Ibutilide middle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide middle dose (0.01 mg/kg + 0.002 mg/kg)
Trial: 9630110
Drug: Ibutilide high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide high dose (0.02 mg/kg + 0.004 mg/kg)
Trial: 10421596
Drug: Ibutilide (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (all doses)
Trial: 7526774
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of oral corticosteroids
Trial: 2464722
Drug: Conventional topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional topical hemostatic agent
Trial: 29043998
Drug: Antiglaucoma medication
RxNorm normalized name: ANTIGLAUCOMA MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiglaucoma medication (drug group)
Trial: 22850760
Drug: Pitavastatin 2
RxNorm normalized name: PITAVASTATIN 2MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg orally with water
Trial: 16885723
Drug: Liquid hemp
RxNorm normalized name: hemp
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid hemp oil (0.39 and 14.8 mg THC/d)
Trial: 16885723
Drug: Hemp oil
RxNorm normalized name: HEMP OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemp oil in capsules (0.47 mg THC/d)
Trial: 16885723
Drug: Dronabinol capsules
RxNorm normalized name: Dronabinol Capsules
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol capsules (7.5 mg THC/d)
Trial: 9357876
Drug: 0.09 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09 mg/kg morphine
Trial: 9357876
Drug: 0.09 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09 mg/kg morphine plus 0.3 mg/kg methylnaltrexone
Trial: 1376847
Drug: Isradipine 2.5
RxNorm normalized name: isradipine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine 2.5 mg twice daily for 3 months
Trial: 4007415
Drug: Adenine arabinoside
RxNorm normalized name: Adenine
DrugBank: Adenine (DB00173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenine arabinoside (Ara‐A) alone (10 mg/kg body wt for 4‐8 weeks)
Trial: 4007415
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (prednisolone 40 mg/day for 4 weeks followed by Ara‐A)
Trial: 27611806
Drug: Propofol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (20 mg IV)
Trial: 26990304
Drug: Midazolam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (2 mg IV)
Trial: 23855406
Drug: Standard prenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prenatal plus brief cognitive behavioural therapy (CBT) initiated between the 20th and 28th gestation week
Trial: 22449251
Drug: Adefovir and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir and lamivudine (100 mg/daily)
Trial: 22449251
Drug: Adefovir alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir alone (10 mg/daily)
Trial: 18698234
Drug: Levodopa treatment
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa treatment in PD patients
Trial: 11773285
Drug: Adjuvant hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormonal therapy offered to women whose tumors express hormone receptor protein
Trial: 11438563
Drug: Anthracyclines in
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracyclines in adjuvant chemotherapy regimens
Trial: 11438563
Drug: Adjuvant dose-intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant dose-intensive chemotherapy regimens
Trial: 8167785
Drug: Hydration treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration treatment
Trial: 25997653
Drug: 40 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg/day of docosahexaenoic acid (DHA)
Trial: 25997653
Drug: 80 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/kg/day of docosahexaenoic acid (DHA)
Trial: 25997653
Drug: 120 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/kg/day of docosahexaenoic acid (DHA)
Trial: 23193009
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (1-4 capsules daily containing 277.8 mg DHA and 39.0 mg EPA)
Trial: 19347696
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) adaptation of the Coping with Stress program, duration not specified.
Trial: 7554633
Drug: Enoxaparin 30
RxNorm normalized name: ENOXAPARIN 30MG/0.3ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 30 mg twice daily
Trial: 10910900
Drug: Flt3 ligand
RxNorm normalized name: Allogeneic natural killer (NK) cells derived from CD34+ human placental stem/progenitor cells. The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flt3 ligand (FL) administration
Trial: 9308064
Drug: Ibuprofen 10
RxNorm normalized name: ibuprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 10 mg.kg‐1
Trial: 8467623
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil (400 mg orally with food twice a day)
Trial: 8467623
Drug: Cefaclor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (500 mg orally, fasting, three times a day)
Trial: 9088820
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments together
Trial: 16467022
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg daily (standard regimen)
Trial: 16467022
Drug: Intermittent terbinafine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent terbinafine 350 mg daily for 2 weeks on, 2 weeks off
Trial: 15221928
Drug: Early therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early therapeutic lymphadenectomy and adjuvant interferon alfa‐2b therapy
Trial: 11534891
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of formoterol
Trial: 11534891
Drug: Repeated dosing
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dosing of formoterol
Trial: 8422839
Drug: Three-injection regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-injection regimen (regular prebreakfast, regular prelunch, and [regular+ultralente] predinner)
Trial: 8422839
Drug: Two-injection regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-injection regimen ([regular+intermediary] prebreakfast and predinner)
Trial: 8422839
Drug: Three-injection regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-injection regimen
Trial: 8422839
Drug: Three-injection regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-injection regimen and Two-injection regimen
Trial: 18520178
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with cedar pollen extract
Trial: 18520178
Drug: Cypress pollen
RxNorm normalized name: Cypress pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cypress pollen specific IgE antibodies
Trial: 14504627
Drug: High group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High group (individual face-to-face counselling up to 1 hour monthly for 1 year)